Skip to main content

Table 1 Clinicopathologic and histomorphologic features in hepatic steatosis patients

From: Expression patterns of STAT3, ERK and estrogen-receptor α are associated with development and histologic severity of hepatic steatosis: a retrospective study

 

NAFLD

(n = 18)

AFLD

(n = 11)

Control

(n = 38)

Clinical Features

   

 Age, mean (range) years

23 ± 6.4 (11–36)a

41 ± 9.5 (23–59)a

61 ± 12.5 (34–89)a

 Sex

   

  male

15 (83%)

9 (82%)

11 (29%)

  female

3 (17%)

2 (18%)

27 (71%)

 BMI

   

  underweight

0

1 (9%)

2 (5%)

  normal

3 (17%)

6 (55%)

13 (34%)

  overweight

0

2 (18%)

15 (39%)

  obese

15 (83%)

2 (18%)

8 (21%)

Liver Biochemistry

   

 AST/ALT ratio

   

  ≤2

14 (78%)

6 (55%)

  > 2

4 (22%)

5 (45%)

 AST, median (mean, range) U/L

79 (67, 11~ 192)

67 (105, 21~ 152)

22 (35, 12~ 249)

 ALT, median (mean, range) U/L

84 (124, 11~ 384)

44 (35, 12~ 204)

17 (31, 7~ 252)

 TB, median (mean, range) mg/dL

0.8 (0.9, 0.5~ 12.4)

14 (9, 0.7~ 19.8)

0.7 (0.8, 0.3~ 3.5)

Histomorphological Features

   

 Steatosis

  

None

  5–33%

4 (22%)

2 (18%)

 

  > 33–66%

5 (28%)

5 (45%)

 

  > 66%

9 (50%)

4 (36%)

 

 Lobular inflammation (inflammatory foci/200× field)

 

None

  < 2

16 (89%)

6 (55%)

 

  2–4

2 (11%)

3 (27%)

 

  > 4

0

2 (18%)

 

 Ballooning degeneration

  

None

  none

9 (50%)

1 (9%)

 

  few

8 (44%)

5 (45%)

 

  many

1 (6%)

5 (45%)

 

 Fibrosis

  

None

  none

6 (33%)

1 (9%)

 

  perisinusoidal or peripota1

11 (61%)

1 (9%)

 

  Perisinusoidal & potal/periportal

1 (6%)

1 (9%)

 

  bridging fibrosis

0

3 (27%)

 

  cirrhosis

0

5 (45%)

 
  1. NAFLD non-alcoholic fatty liver disease
  2. AFLD alcoholic fatty liver disease
  3. Control, 16 cases of biliary cyst and 22 cases of hepatolithiasis
  4. amean ± standard deviation
  5. AST aspartate transaminase
  6. ALT alanine transaminase
  7. TB total bilirubin